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ABSTRACT: Despite their high therapeutic potential, only a limited
number of approved drugs originate from marine natural products. A
possible reason for this is their broad metabolic variability related to the
environment, which can cause reproducibility issues. Consequently, a
further understanding of environmental factors influencing the production
of metabolites is required. Giant barrel sponges, Xestospongia spp., are a
source of many new compounds and are found in a broad geographical
range. In this study, the relationship between the metabolome and the
geographical location of sponges within the genus Xestospongia spp. was
investigated. One hundred and thirty-nine specimens of giant barrel sponges
(Xestospongia spp.) collected in four locations, Martinique, Curaca̧o,
Taiwan, and Tanzania, were studied using a multiplatform metabolomics
methodology (nuclear magnetic resonance spectroscopy and liquid
chromatography−mass spectrometry). A clear grouping of the collected samples according to their location was shown.
Metabolomics analysis revealed that sterols and various fatty acids, including polyoxygenated and brominated derivatives, were
related to the differences in locations. To explore the relationship between observed metabolic changes and their bioactivity,
antibacterial activity was assessed against Escherichia coli and Staphylococcus aureus. The activity was found to correlate with
brominated fatty acids. These were isolated and identified as (9E,17E)-18-bromooctadeca-9,17-dien-5,7,15-triynoic acid (1),
xestospongic acid (2), (7E,13E,15Z)-14,16-dibromohexadeca-7,13,15-trien-5-ynoic acid (3), and two previously unreported
compounds.
■ INTRODUCTION
Marine natural products (MNP) have a wide chemical
diversity, covering a broader area in the chemical spectrum
compared to their terrestrial counterparts.1 The chemical
structures of metabolites isolated from marine organisms
contain highly characteristic features and many of them have
shown diverse bioactivities. In the past decades, the isolation of
novel and bioactive molecules from marine organisms has been
a hot issue in natural product research, resulting, so far, in the
development of eight drugs, which have been approved and are
currently available for the treatment of cancer, HIV, and
pain.2−4 Despite their potential, the number of approved drugs
is low considering the large number of compounds that have
been discovered from marine sources. In fact, while more than
1200 new compounds are reported every year, the number of
MNP-derived approved drugs has not been increasing at the
same rate.1,5,6
Although many of the metabolites produced by marine
organisms have proved to be active, these compounds are
usually produced in very small amounts.7 During the process of
drug development, large quantities of the compound are
required to perform all of the preclinical and clinical trials that
are necessary for a drug to be approved.8 Unfortunately, the
large-scale harvesting of the organism required for this is not
feasible either from an economical or an ecological
perspective.4 Moreover, the production of metabolites in
marine organisms can change due to environmental factors
such as pH, temperature, predation pressure, and subsequent
changes in the symbiont community, making them too
unreliable both qualitatively and quantitatively as a natural
source of compounds.9
To overcome this, diverse approaches have been suggested,
including aqua- and mariculture.7,10 Although these techniques
have not been used yet for the production of compounds at a
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commercial scale, it is thought that their implementation could
provide sufficient amounts of the compounds to meet the
demand for clinical and preclinical trials.11 The successful
cultivation of marine organisms, mainly of sponges,12−14
resulting in the production of higher quantities of active
metabolites,15,16 could guarantee the reliability of the sources,
paving the way for their approval for medicinal use.
Optimization of growth and production conditions for the
cultivation of the organisms requires an understanding of how
biotic and environmental factors affect their metabolome. Such
a study involving so many variables can benefit from the use of
an untargeted approach that allows the acquisition of the most
inclusive picture of the metabolome and then observes how it
varies with changing external factors. Metabolomics, defined as
comprehensive profiling of all of the metabolites produced by
an organism, cell, or tissue at a certain point in time, can
provide the information, which could then be used for
guidance on a variety of compounds produced and uncovering
the factors associated with their production.17
Among marine organisms, sponges have been considered to
be the most prolific in the production of secondary
metabolites, most of which have biological activity as proved
by their performance in a wide variety of bioassays.1,7,18 In
particular, giant barrel sponges, which belong to the genus
Xestospongia, have drawn the attention of the scientific
community due to their pharmacological activities and their
role in ecosystems.19,20 In ecological systems, their large size
allows them to play an essential role in the reef, providing
habitat for other organisms and filtering vast amounts of
seawater.21,22 Therefore, the tight interaction of giant barrel
sponges with their environment makes them an interesting
model to study the relationship between metabolites and
environmental factors. Also, in some locations, these sponges
have been reported to cover up to 9% of the reef substrate,
being more abundant than any other invertebrate.23,24 Their
chemical composition has been studied, and a wide range of
compounds have been isolated including alkaloids, brominated
fatty acids, and sterols. Many of these compounds have proved
to be bioactive, displaying antibacterial, cytotoxicity, fungicide,
and antiretroviral activities.20
In addition, giant barrel sponges can be found in a wide
geographical range: Xestospongia testudinaria, from the Red Sea
to the Indo-Pacific Ocean and Australia, and Xestospongia muta
in the tropical regions of the Atlantic Ocean. These two species
show very similar genetic and morphological markers.25
Furthermore, recent studies revealed the presence of cryptic
species in both ocean basins.26 Interestingly, for this study,
some of the species present in the Caribbean Sea are
genetically much closer to species in the Indo-Pacific Ocean
than to other species in the same location.26,27 These
similarities in the cryptic species between locations provide
the opportunity to focus on the differences in the metabolome
caused by environmental factors.
Geographical location has been identified as one of the most
influential factors related to the variation of many sponge
metabolites.28−30 However, the results that led to this
conclusion were aimed at a few target metabolites, while the
more general effect on the whole metabolome, which requires
a holistic approach, has scarcely been studied.31 To study the
correlation between the geographical location and metabolic
production, 139 specimens of giant barrel sponges (Xesto-
spongia spp.), collected in four different geographic locations,
Martinique, Curaca̧o, Taiwan, and Tanzania, were studied
using a holistic approach. Applying the multiplatform
metabolomics methodology (nuclear magnetic resonance
(NMR) spectroscopy and liquid chromatography−mass
spectrometry (LC−MS)), we aimed to investigate the effect
of geographical location on the chemical composition of the
sponges. Additionally, the correlation between the metabolic
changes observed in the samples and their antibacterial activity
was evaluated. This proved that the implementation of a
metabolomics approach to MNPs can provide relevant
information on the conditions required to optimize the
production of bioactive compounds. Furthermore, the
presence of minor active compounds largely influenced by
location-related factors can be revealed using this approach.
■ RESULTS AND DISCUSSION
The metabolic profile of giant barrel sponge samples collected
in four different geographical locations showed clear differ-
ences in the chemical composition of the specimens collected
in each location. To compare the general metabolic profile of
the samples, 1H NMR and LC−MS were separately applied to
the same sample set. This data was further analyzed using an
orthogonal partial least-squares discriminant analysis (OPLS-
DA) model (Figure 1). Both models, 1H NMR and LC−MS,
were validated with a Q2 value > 0.4 and cross-validation
analysis of variance (CV-ANOVA) test, p < 0.05.32,33
In fact, for giant barrel sponges X. muta and X. testudinaria,
the compositions of sterols34 and some brominated fatty
acids20 were previously found to be similar between sponges
collected in different oceans. These previous studies showed
that despite large geographical separation, giant barrel sponges
could share a common metabolic background in qualitative
features. In this study, however, a significant separation
Figure 1. First two components of the OPLS-DA analysis based on 1H NMR (A) and LC−MS (B) of Xestospongia spp. samples collected in four
locations: Curaca̧o (red), Martinique (green), Taiwan (dark blue), and Tanzania (light blue).
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between the samples collected from different places was
observed in the OPLS-DA analysis (Figure 1). This result
might indicate that the environmental conditions in each
location could quantitatively influence the metabolome of the
sponges.
The location in which sponges grow involves a number of
factors that can influence their development and metabolism,
including abiotic factors such as temperature, pH, salinity, or
the biotic predatory stress. The effect of the combination of
these factors could cause that sponges collected from a specific
location produce similar metabolites. Furthermore, Xestospon-
gia spp. are high microbial abundance (HMA) sponges, and
microbial communities have been reported to mainly be
affected by geographical location.22 Thus, it is plausible to find
differences in the chemical composition of sponges from
different locations, as the metabolome corresponds to the
holobiont and the metabolites found can either be produced by
the sponge, by the microorganisms, or they can be the product
of the interaction of the sponges with microorganisms.2
The loading plots of the OPLS-DA analysis (NMR and LC−
MS data) were analyzed to select the discriminating signals and
subsequently identify the corresponding compounds. The
characteristic 1H NMR chemical shifts are shown in a heat map
in Figure 2, obtained by calculation of the variable importance
for the projection (VIP) values. The signals correlated with the
samples from Martinique were found mainly in two regions of
the spectra. The region between δH 0.80 and 1.00 was assigned
to methyl groups in sterols. Particularly the singlets in the
range of δH 0.7−0.8 were assigned to methyls H-18 and H-19
in sterols. Many steroids have been reported in Xestospongia
spp., including conventional sterols,35 and brominated fatty
acid esters.36 The aromatic region between δH 7.04 and δH
7.32 is characteristic of phenolic signals that could correspond
to known phenolics of Xestospongia such as quinones,37
isoquinoline alkaloids,38 and β-carboline alkaloids.39 Samples
from Curaca̧o were distinguished by abundant signals in the
range of δH 2.50−3.80. Signals downfield of this range (δH
3.0−3.8) correspond to protons attached to oxygen-bearing
carbons. These could thus be attributed to hydroxylated
polyunsaturated fatty acids since there are many reports of the
isolation of this class of fatty acids from Xestospongia spp.40−42
Taiwan samples displayed characteristic signals between δH
6.40 and 6.60, which correspond to double bonds commonly
occurring in brominated unsaturated fatty acids. Samples from
Tanzania had no distinguishing signals in a specific region of
the spectrum, indicating that the changes present in this
location do not involve a family of compounds but rather
specific compounds.
The NMR analysis provided a general overview of the
metabolic profiles, allowing the detection of families of
compounds predominant in each location. However, the
congestion of signals in the spectra and the relatively low
sensitivity rendered the identification of individual metabolites
unfeasible. Thus, LC−MS/quadrupole time-of-flight (Q-TOF)
was used to identify these metabolites, especially the minor
ones. As shown in Figure 1b, metabolic differences in the
samples from each location were as clear as those observed
with 1H NMR. As in the case of 1H NMR, a VIP plot was also
used for the identification of peaks responsible for the
separation. However, dereplication of the 50 most relevant
peaks obtained from the VIP plot was not successful because
most of the selected MS features could not be identified or
they corresponded to several isomers. Nevertheless, informa-
tion on a specific metabolite group, brominated fatty acids, was
obtained from the MS data. Different types of brominated fatty
acids were found as marker features in the samples on each
location. The Martinique samples showed no bromine-
containing signals, while the Curaca̧o samples were discrimi-
nated by their characteristic dibrominated metabolites and the
samples from Taiwan and Tanzania by monobrominated ones.
The variation in the chemical composition of the samples
observed in this study proves the plasticity of Xestospongia spp.
in terms of their biosynthesis processes. This could partly
explain the great diversity in compounds isolated from this
same sponge genus all over the world. Considering that these
compounds exhibit a wide range of biological activities, it could
be presumed that this metabolic differentiation observed in
samples from different locations could be reflected in their
bioactivity.28 To investigate this potential correlation, the
antimicrobial activity of Xestospongia spp. extracts against a
Gram-positive (S. aureus) and a Gram-negative (E. coli)
bacteria was assayed. This particular bioactivity was chosen
due to numerous reports of antimicrobial compounds in
Xestospongia spp. collected throughout the world.43,44
The result of the activity test showed that some sponge
extracts were active against S. aureus at a concentration of 512
μg/mL. From the whole sample set, 11.5% of the collected
samples displayed activity, although there was a large variation
in the activity according to the location. For example, while
20% of the samples collected in Taiwan had antimicrobial
activity, none of the samples from Tanzania displayed activity.
This indicates that the ratio of active and nonactive samples
was not significantly related to the collection places (χ2(2) =
2.72, p = 0.256). The lack of correlation between these two
factors suggests that the production of antibacterial com-
pounds is triggered by a factor occurring within a smaller
spatial scale or is driven by genetic variation.
Figure 2. Heat map of characteristic signals from 1H NMR data
obtained from the variable importance for the projection (VIP) plot
of orthogonal partial least-squares discriminant analysis (OPLS-DA).
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On the other hand, none of the samples showed activity
against E. coli, a proteobacteria, when tested at a concentration
of 512 μg/mL. The lack of activity against E.coli can be
explained by the fact that proteobacteria are one of the most
predominant phyla among the bacterial communities of
Xestospongia spp.22,45 Therefore, it is a natural result that
they do not produce compounds that could inhibit the growth
of these types of bacteria.
To identify the compounds specifically involved in the
antibacterial activity against S. aureus, an OPLS-DA model was
built, grouping the samples as active (showed activity at 512
μg/mL) and nonactive (no activity shown at concentrations of
512 μg/mL) and using both NMR and LC−MS data. The
model based on the NMR data was not validated and did not
reveal differences between the two groups. In this case,
overlapping of signals belonging to compounds of the same
family or low sensitivity could explain the lack of validation, as
the activity must be related to specific compounds. On the
other hand, with the LC−MS data, it was possible to separate
the samples that displayed activity from the nonactive samples
as shown in Figure 3. Although variation in the chemical
composition among the active samples was observed, a list of
the masses of potentially active compounds was made using an
S-plot (Supporting Information Table S2). These features,
together with the list obtained previously from the OPLS-DA
analysis using location as a factor, were used to target the
compounds of interest from samples collected in Martinique,
Curaca̧o, and Taiwan. The great dispersion observed between
the active samples suggested that although all samples
exhibited activity, it was not necessarily due to the same
compounds or, alternatively, that there was a significant
variation in the number of active compounds present in the
samples depending on the location. To clarify this, some of the
most active compounds were isolated and tested, and their
resulting activity was compared with their occurrence in
different locations.
Isolation and Structural Elucidation. Ethanolic extracts
of samples from Martinique, Curaca̧o, and Taiwan that were
active against S. aureus were prepared to isolate potentially
active antimicrobial compounds. These extracts were subjected
to fractionation with liquid chromatography using the list of
potential active features as a criterion for fraction selection.
This led to the isolation of five brominated fatty acid analogues
(Figure 4): two from Martinique extracts (1, 2), two from
Curaca̧o extracts (3, 4), and one from Taiwan extracts (5).
Compound 1 was isolated from a Martinique sample as a
white powder. The (+)-HRESIMS spectrum of 1 showed the
proton adduct [M + H]+ ions at m/z 347.0646 and 349.0631,
with relative intensities of 1:1, suggesting the presence of one
bromine atom in the molecule. The molecular formula was
deduced to be C18H19BrO2. The
1H NMR (CH3OH-d4, 600
MHz) spectrum (Supporting Information Figure S3) of the
compound showed the presence of two double bonds and the
13C NMR (CH3OH-d4, 150 MHz) showed one carboxylic acid
carbon and the presence of three triple bonds. The molecular
formula, together with the characteristic NMR signals, was
dereplicated using the Dictionary of Natural Products. The
compound was identified as (9E,17E)-18-bromooctadeca-9,17-
dien-5,7,15-triynoic acid, which had been previously isolated
from X. muta collected in Columbus Island, Bahamas, and
reported to inhibit the HIV-1 protease with an IC50 of 8 μM.
46
Compound 2 was also isolated from a Martinique sample as
a white powder. The (+)-HRESIMS spectrum of 2 showed the
proton adduct [M + H]+ ions at m/z 351.0956 and 353.0939,
with relative intensities of 1:1. This isotopic pattern suggested
the presence of a bromine atom in the molecule. The
molecular formula was deduced to be C18H23BrO2. The
1H
NMR (CH3OH-d4, 600 MHz) spectroscopic data (Supporting
Information Figure S7) showed the presence of two double
bonds and 13C NMR (CH3OH-d4, 150 MHz) showed the
presence of two triple bonds. A search using the molecular
formula and the characteristic NMR signals in the Dictionary
of Natural Products yielded the compound (9E,17E)-18-
bromooctadeca-9,17-dien-7,15-diynoic acid, also known as
Figure 3. Orthogonal partial least-squares discriminant analysis
(OPLS-DA) model for the 139 Xestospongia spp. samples categorized
by their activity against S. aureus using LC−MS data.
Figure 4. Structure of the compounds isolated from the giant barrel
sponge (Xestospongia spp.). (9E,17E)-18-bromooctadeca-9,17-dien-
5,7,15-triynoic acid (1), xestospongic acid (2), (7E,13E,15Z)-14,16-
dibromohexadeca-7,13,15-trien-5-ynoic acid (3), compound (4), and
compound (5).
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xestospongic acid. This compound had been originally isolated
from Xestospongia sp. samples collected in Australia as one of
the most abundant compounds in the sample, accounting for
0.1% of the dry weight material.47
Compound 3 was isolated from a Curaca̧o sample as a white
powder. Its (+)-HRESIMS spectrum showed the proton and
sodium adduct [M + H]+ and [M + Na]+ ions at m/z
402.9904, 404.9884, and 406.9867, and 424.9727, 426.9706,
and 428.9685, respectively, both having a relative intensity of
1:2:1. This isotopic pattern indicates the presence of two
bromine atoms in the molecule. The molecular formula was
deduced to be C16H20Br2O2.
1H NMR (CH3OH-d4, 600
MHz) spectroscopic data (Supporting Information Figure
S11) showed the presence of three double bonds in the
molecule and the 13C NMR (CH3OH-d4, 150 MHz) showed
one carboxylic acid carbon and one triple bond. The molecular
weight together with the NMR signal in the Dictionary of
Natural Products led to the identification of the compound as
(7E,13E,15Z)-14,16-dibromohexadeca-7,13,15-trien-5-ynoic
acid. This compound had been previously reported from X.
muta collected in Summerland Key, Florida, and in Portobelo
Bay, Panama.́48,49
Compound 4 was also isolated from a Curaca̧o sample as a
white powder. Its (+)-HRESIMS spectrum showed the proton
and sodium adducts [M + H]+ and [M + Na]+ ions at m/z
639.0777, 641.0761, and 643.0749 and 661.0580, 663.0581,
and 665.0563, respectively, both sets of ions with a relative
intensity of 1:2:1. This isotopic pattern indicates the presence
of two bromine atoms in the molecule. The molecular formula
was deduced to be C25H36Br2O9, which requires 7 degrees of
unsaturation. The 1H NMR and 13C NMR spectroscopic data
(Table 1) and heteronuclear single quantum correlation
(HSQC) spectrum revealed 10 methylene (δH/δC 1.40/29.5,
1.44/29.1, 1.82/25.2, 2.04/32.0, 2.08/33.6, 2.35/19.4, 2.48/
33.8, 3.67−3.87/62.7, 3.92−3.66/71.9 4.17/66.7), six methine
(δH/δC 3.21/75.1, 3.28/78.0, 3.29/71.6, 3.36/77.9, 4.00/69.6,
4.28/104.7), and five olefinic protons (δH/δC 5.45/111.3,
5.99/144.0, 6.07/137.4, 6.56/113.4, 6.78/132.3). The signal at
104.7 ppm is very characteristic for a carbon atom joined to
two oxygen atoms, which indicates the presence of a sugar
moiety in the molecule. In addition, the 13C NMR spectrum
showed four nonprotonated carbons, consisting of one ester
carbonyl (δC 174.9), two sp carbons (δC 80.9, 88.1), and one
olefinic carbon (δC 114.8). The presence of aliphatic signals
together with a carbonyl and sp and sp2 carbons indicates that
the structure contains an unsaturated fatty acid moiety. Two of
the olefinic carbons are shifted upfield, indicating the presence
of a substituent that increases the protection over those
carbons. This is in agreement with the presence of two
bromine atoms observed in the mass spectra and with the lack
of any terminal methyl or methylene groups. It was thus
possible to establish the attachment of bromine atoms to
terminal olefinic carbons at δc 114.8 and δc 113.4.
Further examination of HMBC and COSY correlations
allowed us to establish the full structure of compound 4
(Figure 5) as consisting of three moieties: a dibrominated
unsaturated fatty acid, a glycerol molecule, and a sugar moiety.
The brominated fatty acid and the sugar are attached to C1
and C3 of the glycerol molecule, respectively. The chemical
shift of δc 104.7 was assigned to the anomeric carbon of the
sugar, which is attached to C3 of the glycerol moiety through a
glycosidic bond. Additionally, NOESY showed correlations
between the anomeric proton and those in positions 3″ and 5″.
This correlation, together with the coupling constants of the
anomeric proton (J = 7.8 Hz) and protons 3″ and 4″ (J > 8
Hz) obtained from J-Resolved spectra, allowed the identi-
fication of the sugar moiety as β-glucose. This was also
supported by reported 13C NMR chemical shifts of the β-
glucose moiety in similar compounds.50,51 The identical
chemical shift and coupling constant of H-13′ indicated that
the double bond in position 13′ would have the same
configuration as that of compound 3. Lastly, the double bond
in position 7′ was confirmed to have an E configuration with
its characteristic coupling constant (J = 15.8 Hz), while the
Table 1. NMR Spectroscopic Data for Compounds 4 and 5a




1H NMR δ, (J
in Hz)
13C NMR
δ, type 1H NMR δ, (J in Hz)
1′ 174.9, C 174.6, C
2′ 33.8,
CH2















5′ 88.1, C 76.8, C
6′ 80.9, C 66.3, C
7′ 111.3,
CH






































6.78 dm (7.6) 78.3, Cb
16′ 113.4,
CH
6.56 d (7.6) 93.8, C
17′ 119.2
CH
















4.21 dd (11.4, 4.5),
4.14 dd (11.4, 6.2)
1″ 104.7,
CH
4.28 d (7.8) 67.0,
CH2
3.66 m
2″ 75.1, CH 3.21 m 60.4,
CH2
4.31 m
3″ 77.9, CH 3.36 bs
4″ 71.6, CH 3.29 m








aNMR spectra were recorded in CH3OH-d4,
1H 600 MHz, and 13C
150 MHz. bThese carbons are interchangeable.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c01151
ACS Omega 2020, 5, 12398−12408
12402
terminal double bond was found to have a Z configuration with
the coupling constant (J = 7.6 Hz)48,49
Compound 5 was isolated from a sample from Taiwan as a
white powder. The (+)-HRESIMS spectrum of 5 showed the
proton adduct [M + H]+ ions at m/z 588.1718 and 590.1702.
The ions have a relative intensity of 1:1, indicating the
presence of a bromine atom in the molecule. The molecular
formula was deduced to be C26H39BrNO7P. The
1H NMR and
ATP 13C NMR spectroscopic data (Table 1) and HSQC
correlation revealed the presence of three overlapping methyl
groups joined to a nitrogen atom (δH/δC 3.24/54.7 × 3), 13
methylene (δH/δC 1.43/29.4, 1.43/29.3, 1.54/29.3 × 2, 1.83/
24.8, 2.28/19.6, 2.30/19.9, 2.35/19.2, 2.49/33.7, 3.66/67.0,
3.92/67.8, 4.14−4.21/66.3, 4.31/60.4), one methyne (δH/δC
3.99/69.8), two olefinic protons (δH/δC 6.24/119.2, 6.70/
117.9), and seven carbons with no protons attached, consisting
of one carbonyl ester (δC 174.6) and six sp carbons (δC 66.3 ×
2, 76.8, 78.2, 78.3, 93.8). The sp carbons indicate the presence
of three triple bonds in the molecule. However, some of the δC
are shifted downfield, suggesting that two of the triple bonds
are conjugated. As for compound 5, the lack of a terminal
methyl or methylene along with the low chemical shift of the
olefinic carbon indicates the presence of a terminal olefinic
bond attached to a bromine atom. Further examination of
HMBC and COSY correlations established the structure of 5
(Figure 6) as consisting of three moieties: a brominated fatty
acid, a molecule of glycerol, and a molecule of phosphati-
dylcholine. The presence of a phosphate group can be deduced
from analysis of the exact mass of the molecule.
All of the isolated compounds contained one or more triple
bonds in their structures; thus, they are classified as
polyacetylenes. These kinds of compounds have been reported
in a wide range of marine organisms such as algae, corals,
mollusks, and sponges. In the case of sponges, the genera
Petrosia, Callyspongia, and Xestospongia are the main sources of
polyacetylene compounds, and, in some cases, they have even
been considered to be a chemotaxonomic marker of these
genera.52 Although the biosynthetic pathway and ecological
function of these kinds of compounds are still unclear, they
have shown a wide range of biological activities. In this study,
all of the isolated compounds exhibited mild activity against S.
aureus (1: 64 μg/mL, 2: 256 μg/mL, 3: 64 μg/mL, 4: 64 μg/
mL, 5: 128 μg/mL). Thus, the inconsistency in the
relationship between the activity and location in which the
sponges were collected can be explained by the fact that the
compounds responsible for the activity might differ in their
concentration or their structure in each location.
A comparison of the occurrence of the isolated compounds
between the locations showed different patterns for each
compound (Figure 7). Interestingly, compound 2, isolated
from a sample collected in Martinique, was more abundant in
samples from the other three locations. This compound has
been previously isolated from Xestospongia spp. samples
collected in Australia,47 the Red Sea,53 and Mayotte on the
coast of Africa.44 The occurrence of 2 in Xestospongia spp.
samples collected all over the world indicates that although it is
a constitutive metabolite of sponges of the genus Xestospongia,
the environmental factors prevalent in each location may affect
the amount in which this metabolite is produced.
Compounds 3 and 4 were more abundant in samples from
the Caribbean region, mainly Curaca̧o. Both compounds have
two atoms of bromine in their structures that distinguish them
from the other compounds isolated in this study. Compound 4
as such has not been previously reported, but its fatty acid
moiety corresponds to compound 3. Moreover, compound 3
has been previously isolated from a sample collected in
Florida48 and Pańama.49 Since these compounds occur mainly
in the Caribbean region, they might be used to distinguish the
sponges from this region. Lastly, compound 5 is a
phospholipid from the phosphatidylcholine group. These
compounds are known to be part of the cellular membrane
in animals, having not only structural functions but also playing
a role in the signaling of metabolic pathways.54 The variability
observed in the amount of 5, which is more abundant in
samples from Taiwan and Tanzania than samples from the
Caribbean, suggests that similarly to what occurs in animal cell
membranes, this compound also has more than just a structural
role in Xestospongia spp. and its production is thus conditioned
by the environmental factors related to each location.
■ EXPERIMENTAL SECTION
Sample Collection and Extraction. Xestospongia spp.
samples were collected in Martinique, Curaca̧o, Tanzania, and
Taiwan, and stored in ethanol at −20 °C (Supporting
Information Table S1). Samples were transported to the
Institute of Biology of Leiden University for further analysis.
The Xestospongia samples were ground and extracted with
ethanol and sonicated for 20 min. The extraction was done in
triplicate. An aliquot of 1 mL of each extract was dried and
used for 1H NMR analysis. The remaining extracts were dried.
The salt from the extracts was removed using C-18 SPE
Supelco Supelclean LC-18 (Merck, Darmstadt, Germany)
cartridges. For each extract, 50 mg were loaded into the
cartridge and eluted with solvents of decreasing polarity, i.e.,
H2O (F1), MeOH (F2), and MeOH/DCM (1:1) (F3). The
methanol fraction (F2) was used for further LC−MS analysis.
Metabolomic Study. 1H NMR Analysis and Data
Preprocessing. The dry extract was resuspended in 1 mL of
deuterated methanol (CH3OH-d4) with hexamethyl disiloxane
(HMDSO) as the internal standard. The 1H NMR spectra
were measured at 25 °C in an AV-600 MHz NMR
Figure 5. Important COSY, HMBC, and NOE correlations of
compound 4.
Figure 6. COSY and HMBC important correlations of compound 5.
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spectrometer (Bruker, Karlsruhe, Germany), operating at the
1H NMR frequency of 600.13 MHz, and equipped with a TCI
cryoprobe and a Z gradient system. For internal locking,
CH3OH-d4 was used. A presaturation sequence was used to
suppress the residual water signal, using low-power selective
irradiation at the H2O frequency during the recycle delay.
The resulting spectra were phased, baseline corrected and
calibrated to HMDSO at 0.07 ppm using TOPSPIN V. 3.0
(Bruker, Karlsruhe, Germany). The NMR spectra were
bucketed using AMIX 3.9.12 (Bruker BioSpin GmbH,
Rheinstetten, Germany). Bucket data was obtained by spectra
integration at 0.04 ppm intervals from 0.20 to 10.02 ppm. The
peak intensity of individual peaks was scaled to the total
intensity of the buckets. The regions between 3.32 and 3.28,
4.9 and 4.8, 3.62 and 3.57, and 1.15 and 1.19 ppm were
excluded from the analysis because they correspond to solvent
residual signals.
LC−MS Analysis and Data Processing. The methanol
fractions obtained from the SPE were dried, and 1 mg was
dissolved in ACN/H2O 1:1 to obtain solutions with a final
concentration of 1 mg/mL. The fractions were analyzed using
a UHPLC-DAD-MS, Thermo Scientific (Dreieich, Germany)
UltiMate 3000 system coupled to a Bruker (Bremen,
Germany) OTOF-Q II spectrometer with electrospray
ionization (ESI). The UHPLC separation was performed on
a Phenomenex (Utrecht, The Netherlands), Kinetex, C18 (2.1
mm × 150 mm, 2.6 μm), using a two-step gradient of 0.1%
formic acid in H2O (A) and 0.1% formic acid in ACN (B),
starting at 45% B to 60% for 15 min, 60−90% for 12.5 min,
and 90−98% B for 2.5 min. The flow rate was 0.300 mL/min,
and the column temperature was maintained at 40 °C. The
injection volume was set at 1 μL. The mass spectrometer
parameters were set as follows: nebulizer gas 2.0 bar, drying gas
10.0 mL/min, temperature 250 °C, and capillary voltage 3500
V. The mass spectrometer was operated in positive mode with
a scan range of 100−1650 m/z and sodium formate was used
as a calibrant.
The resulting chromatogram was processed to obtain a
matrix for further analysis using Brucker Daltonics Profile
Analysis (version 2.1, Bremen, Germany). The spectra were
divided into buckets of 1 min between 1 and 30 min and 1 m/z
between 100 and 1450 m/z. The buckets were organized in a
matrix, and the data was filtered to remove those buckets that
presented a %CV above 20% in the quality control samples.
Statistical Analysis. The matrixes obtained from the NMR
and LC−MS were used to perform multivariate data analysis
using SIMCA-P software (version 15.0.2, Umetrics, Umeå,
Sweden). Principal component analysis, PCA, discriminant
Figure 7. Intensity of the buckets of the most intense peak of the mass spectra for compounds 1−5 in each location. Error bars indicate the
standard error. Results of a Kruskal−Wallis test are shown in each graph. Different letters indicate significant differences in the post-hoc test.
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analysis of partial least-squares, PLS-DA, and orthogonal
partial least-squares, OPLS-DA, were performed. For the
analysis, data was scaled using united variance scaling (NMR)
and pareto scaling (LC−MS), and the models were tested
using a permutation test and a cross-validation ANOVA (CV-
ANOVA) test. The model was considered valid if CV-ANOVA
showed p < 0.05. For the prediction power of the model, Q2
values above 0.4 were required; otherwise, the model was
considered valid but with no prediction power.
A heat map was created using a data matrix with the top 40
signals of the VIP plot. This matrix was uploaded on the
MetaboanalystR 2.0 Web site (http://www.metaboanalyst.
ca).55 The dendrogram was obtained by hierarchical cluster
analysis using the Euclidean distance and the “Ward”
algorithm.
To test if the concentration of each compound differed
among locations, the intensity of buckets corresponding to the
most intense ion observed in its mass spectra was used. Data
was analyzed with IBM SPSS Statistics version 22 (Armonk,
NY) using a Kruskal−Wallis Test. Location was used as a
factor, and the number of samples was 139. For the
compounds that appeared to be significantly different between
locations, a post-hoc test was done, and the P values were
Bonferroni-corrected.
Isolation and Elucidation. For the isolation of active
compounds, extracts of samples from Martinique, Curaca̧o,
and Taiwan were prepared as mentioned in the Sample
Collection and Extraction in Experimental Section. The crude
extracts were fractionated using an SPE 20 mL LC-18 Supelco
Supelclean (Merck, Darmstadt, Germany) cartridge and eluted
using two different methods according to the sample location.
The sample from Martinique (1.0 g) was eluted with 100 mL
of H2O, MeOH, and MeOH/DCM (1:1), yielding three
fractions: FM1, FM2, and FM3, respectively. The samples
from Curaca̧o (1.9 g) and Taiwan (2.5 g) were eluted using 50
mL of each of the following solvents: 100% H2O; H2O/MeOH
8:2, H2O/MeOH 6:4, H2O/MeOH 4:6, H2O/MeOH 2:8,
100% MeOH, and MeOH/DCM 1:1. This resulted in seven
fractions of each extract FC1−FC7 for Curaca̧o samples and
FT1−FT7 for Taiwan samples, respectively.
Fraction FM2 (212 mg) was submitted to a size-based
separation. The fraction was resuspended in 10 mL of MeOH
and injected into a Sepacore Flash System (Büchi, Hendrik-
Ido-Ambacht, The Netherlands) with a Sephadex LH-20
(Merck KGaA, Darmstadt, Germany) column and a sample
loop of 20 mL. Samples were eluted at a flow rate of 2.5 mL/
min with MeOH. Fractions were collected automatically every
minute and combined into nine FM2.1−FM2.9 fractions based
on their TLC profiles. The purification of fractions FM2.7,
FM2.9, FC4, and FT4 was performed using an Agilent (Santa
Clara, CA) 1200 series system on a Phenomenex (Utrecht,
The Netherlands) Luna 5 μm, C-18, 250 mm × 10 mm
column and eluted at a flow rate of 3.50 mL/min with different
gradients of 0.1% formic acid in H2O (A) and 0.1% formic acid
in MeOH (B). Fractions FM2.7−FM2.9 (49.87 mg) were
eluted with a gradient of 75−80% B for 25 min, 80% B for 15
min, 80−100% B for 2 min, and 100% B for 5 min. This
yielded 2.26 mg of 1 and 1.58 mg of 2. Fraction FC4 (70.6
mg) was eluted using the following gradient: 72−85% B for 52
min, 85−100% B for 2 min, and 100% B for 10 min. This
allowed the isolation of 3 (7.16 mg) and 4 (2.14 mg). Fraction
FT5 (94.08 mg) was eluted using the following gradient: 72−
80% B for 34 min, 80−85% B for 16 min, 85−100% B for 3
min, and 100% B for 3 min. This led to compounds 5 (1.51
mg) and 1 (1.00 mg).
(9E,17E)-18-Bromooctadeca-9,17-dien-5,7,15-triynoic
Acid (1). White amorphous powder; 1H NMR (CH3OH-d4,
600 MHz) δH 1.52 m, 1.82 quint (J = 7.3 Hz), 2.18 m, 2.29 m,
2.31 m, 2.38 t (J = 7.0 Hz), 5.55 dm (J = 15.9 Hz), 6.23 m,
6.27 m, 6.70 d (J = 14.0 Hz). 13C NMR (CH3OH-d4, 150
MHz) δc 19.5, 19.6, 25.8, 28.6, 28.6, 33.2, 36.9, 65.9, 73.3,
73.9, 80.2, 83.3, 92.8, 109.8, 117.7, 118.9 and 148.3. HRESIMS
m/z [M + H]+ 347.0646 and 349.0631 (calcd for
C18H20BrO2
+, 347.0647 and 349.0626).
Xestospongic Acid (2). White amorphous powder; 1H
NMR (CH3OH-d4, 600 MHz) δH 1.43 m, 1.49 m, 1.51 m, 1.63
quint (J = 7.5 Hz), 2.09 m, 2.24 m, 2.26 m, 2.28 m, 5.45 dm (J
= 15.8 Hz), 5.96 dt (J = 15.8, 7.2 Hz), 6.22 dt (J = 14.0, 2.3
Hz), 6.68 d (J = 14.0 Hz). 13C NMR (CH3OH-d4, 150 MHz)
δC 19.8 × 2, 26.3, 28.9, 29.2, 29.7, 29.8, 33.3, 36.6, 78.3, 80.2,
89.2, 93.6, 111.6, 117.9, 119.2, and 143.3. HRESIMS m/z [M




ynoic Acid (3). White amorphous powder; 1H NMR
(CH3OH-d4, 600 MHz) δH, 1.40 m, 1.44 m, 1.78 quint (J =
7.2 Hz), 2.04 m, 2.08 m, 2.34 dt (J = 2.0, 7.0 Hz), 2.40 t (J =
7.4 Hz), 5.45 dm (J = 15.8 Hz), 5.99 dt (J = 15.8, 7.1 Hz),6.07
td (J = 7.7, 1.5 Hz), 6.55 d (J = 7.6 Hz), 6.78 dm (J = 7.6 Hz).
13C NMR (CH3OH-d4,150 MHz) δc 19.4, 25.4, 29.1, 29.5,
32.0, 33.6, 33.9, 80.8, 88.1, 111.3, 113.4, 114.8, 132.3, 137.4,
143.9 and 177.3. HRESIMS m/z [M + H]+ 402.9904,
404.9884, 406.9867 (calcd for C16H21Br2O2
+, 402.9903,
404.9883, 406.9862) and [M + Na]+ 424.9727, 426.9706,
428.9685 (calcd for C16H20Br2NaO2
+, 424.9723, 426.9702,
428.9682).
Compound 4. White amorphous powder; 1H NMR
(CH3OH-d4, 600 MHz) δH in Table 1.
13C NMR (CH3OH-
d4, 150 MHz) δC in Table 1. HRESIMS m/z [M + H]
+
639.0777, 641.0761, 643.0749 (calcd for C25H37Br2O9
+,
639.0804, 641.0784, 643.0763) and, [M + Na]+ 661.0580,
663.0581, 665.0563 (calcd for C25H36Br2NaO9
+, 661.0624,
663.0603, 665.0583)
Compound 5. White amorphous powder; 1H NMR
(CH3OH-d4,600 MHz) δH in Table 1.
13C NMR (CH3OH-
d4, 150 MHz) δC in Table 1. HRESIMS m/z [M + H]
+
588.1718, 590.1702 (calcd for C26H40BrNO7P
+ m/z 588.1726,
590.1705)
Antibacterial Activity Test. Bacterial Strains. The strains
used in this study were the Gram-positive bacteria S. aureus
(CECT976) and Gram-negative bacteria E. coli (DH5α,
Promega). The strains had been kept at −80 °C (in 100%
glycerol). For their use, the strains were transferred onto
Mueller−Hinton agar plates (MHA) (Sigma-Aldrich, Zwijn-
drecht, The Netherlands) and incubated overnight at 37 °C.
Antimicrobial Testing by the Microdilution Method. A
broth microdilution method was used to determine the
minimum inhibitory concentration (MIC) according to the
CLSI (Clinical Laboratory Standards Institute) guidelines
using 96-well microtiter plates. The MIC is defined as the
lowest concentration of each extract, which completely inhibits
bacterial growth. For antimicrobial testing, the extracts were
dissolved in 100% dimethyl sulfoxide (DMSO) in a
concentration of 10 mg/mL. All experiments were performed
in triplicate. Ninety microliters of Mueller−Hinton broth
(MHB) and 10 μL of the tested extract were added into the
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first well. Then, 2-fold serial dilutions of the extracts were
prepared by dilution with MHB to achieve a decreasing range
of concentrations from 512 to 516 μg/mL in the microtiter
plates. The highest concentration of DMSO after dilution was
<5%, to avoid affecting the growth of the bacterial strains.
From the overnight cultures of the bacterial strains, a single
colony was used to inoculate the MHB at 37 °C with agitation
(150 rpm). The cultures were then further diluted in MHB and
adjusted to a turbidity level of 0.5 McFarland standard solution
(approximately 106 CFU/mL). Each well was then inoculated
with 50 μL of the bacterial solution at a density of 106 CFU/
mL. Spectinomycin (100 mg/mL) (Sigma-Aldrich, Zwijn-
drecht, The Netherlands) was used as a positive control and
5% DMSO as a negative control. The inoculated microtiter
plates were incubated at 30 °C for 24 h. Bacterial growth was
detected by optical density.
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